The current testing recommendation is to include HER2 mutation testing upfront as part of broad molecular profiling for NSCLC patients with advanced or metastatic disease, in particular, if approved therapies are available [1, 35]. Here, ERBB2 is linked to non-small cell lung carcinoma.